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due to severe hyperinsulinism in patients with
1p36 deletion syndrome and a Prader-Willi-like
phenotype
Stefano Stagi1,4*, Elisabetta Lapi2, Marilena Pantaleo2, Francesco Chiarelli3, Salvatore Seminara1
and Maurizio de Martino1Abstract
Background: Deletion of the subtelomeric region of 1p36 is one of the most common subtelomeric deletion
syndromes. In monosomy 1p36, the presence of obesity is poorly defined, and glucose metabolism deficiency is rarely
reported. However, the presence of a typical Prader-Willi-like phenotype in patients with monosomy 1p36 is controversial.
Case presentation: In this report, we describe two female patients, one who is 6 years 2 months of age and another
who is 10 years 1 month of age, both referred to our hospital for obesity and a Prader-Willi-like phenotype. These patients
presented with severe obesity (body mass index [BMI] was 26.4 and 27.7, respectively), hyperphagia and developmental
delay. Analysis of basal hormone levels showed normal thyroid function and adrenal function but considerable basal
hyperinsulinism (the insulin levels were 54.5 and 49.2 μU/ml, respectively). In patient 1, glycaemia was 75 mg/dl (HOMA-R
10.09), and the HbA1c level was 6.1%; in patient 2, glycaemia was 122 mg/dl, and the HbA1c level was 6.6% (HOMA-R
14.82). An oral glucose tolerance test demonstrated impaired glucose tolerance and diabetes mellitus with marked insulin
resistance (the peak insulin level for each patient was 197 and 279 μU/mL, respectively, while the 120’ insulin level of each
patient was 167 and 234 μU/mL, respectively).
Conclusion: some patients with monosomy 1p36 may show Prader-Willi-like physical and physiologic characteristics
such as obesity and hyperinsulinism with impaired glucose metabolism, which can cause type II diabetes mellitus. Further
studies are necessary to evaluate these findings.
Keywords: Monosomy 1p36, Deletion 1p36, Developmental delay, Mental retardation, Seizures, Obesity, Hyperinsulinism,
Impaired glucose tolerance, Hyperphagia, Prader-Willi-like phenotypeBackground
Deletion of the subtelomeric region of 1p36 is one of
the most common subtelomeric deletion syndromes,
with an estimated incidence of 1 in 5000 to 1 in 10,000
live births [1-3]. The four classes of rearrangements
identified in individuals with monosomy 1p36 in order
of frequency are as follows: apparently pure/simple ter-
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reproduction in any medium, provided the orinterstitial deletions (10%), and complex rearrange-
ments (7%) [4].
Monosomy 1p36 is responsible for a cluster of charac-
teristic clinical features including mental retardation and
multiple congenital abnormalities caused by haploinsuffi-
ciency of numerous contiguous genes [1], such as deep-set
eyes, straight eyebrows positioned low on the supra-orbital
ridges, asymmetric ears, a pointed chin, and a flat nasal
bridge [1]. Additional features include cardiomyopathy,
hearing impairment, seizures [5,6], and a variety of neo-
plasms due to the loss of numerous tumour-suppressor
genes that are located in this chromosomal region [7,8].d. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited.
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or glucose metabolism disorders is rarely reported. How-
ever, the presence of a typical Prader-Willi-like phenotype
in patients with 1p36 monosomy is controversial.
Case presentation
In this report, we describe two female subjects with
monosomy 1p36 and Prader-Willi-like phenotype who
also exhibit type II diabetes and impaired glucose tolerance
due to hyperinsulinism. We provide data both for and
against this possible association. Written informed consent
was obtained from the parents before publication of this
case report and any accompanying images.
Clinical report 1
A female patient, 6 years 2 months of age, was referred
to our Paediatric Endocrinology Unit for severe obesity.
The proposita was the third-born child (the first preg-
nancy was interrupted because of a disorder involving
chromosome 7) of a nonconsanguineous marriage who
was delivered normally at 40 weeks after an uncompli-
cated pregnancy. The family history was unremarkable,
particularly for obesity, which was present only in a pater-
nal uncle. The Apgar score was 5I-7V-8X, and the infant
required oral and gastric suctioning, as well as oxygen and
stimulation upon delivery to treat cyanosis. Birth weight
was 2.175 kg (-2.67 SDS; <3rd centile), length was 44 cm
(-2.92 SDS; <3rd centile), and head circumference was
32 cm (-2.01 SDS; <3rd centile). The neonatal screening
for congenital hypothyroidism was negative.
She presented with abnormal psychomotor develop-
ment, as she sat upright at 8 months, began to walk in-
dependently at 15 months and began to use language at
15 months.
At 6 yrs, 2 months of age, this patient weighed 32.000 kg
(1.73 SDS; > > 97th centile), her height was 110 cm (-1.34
SDS; 3-10th centile), and her occipital-frontal circumference
was 45.8 cm (-2.65 SDS; <3rd centile). This patient’s BMI
was 26.4 (2.41 SDS; > > 97th centile), and the pubertal
staging was defined as B1-PH2-3-AH2. Her blood pres-
sure evaluation showed both systolic and diastolic
hypertension (124/85 mmHg).
Numerous dysmorphic features were observed, includ-
ing a small mouth with heaped-up palate, a small chin, a
small folded ear, straight eyebrows, fifth finger clinodactyly
and short toes. Examination of the subject's mother re-
vealed some mild dysmorphism, clinodactyly of the fifth
finger and a mild learning disability (Figure 1a; Table 1).
Assessment of basal hormone levels showed normal free
thyroxine (1.63 ng/dL; range 0.8-1.9), TSH (3.51 μIU/mL;
range, 0.4-4.0), cortisol (12.3 μg/dL; range 5-19) and ACTH
(21.1 ng/L; range 9.0-52.0) values. The blood count was also
normal. Her blood chemistry was AST: 45 IU/L, ALT:
35 IU/L, γ-GTP: 27 IU/L, HbA1c: 6.1%, TG: 132 mg/dL,total cholesterol: 195 mg/dL, HDL: 51 mg/dL, insulin: 54.5
μU/ml, glycaemia: 102 mg/dl (HOMA 13.72). A screening
for coeliac disease was negative (IgA 142 mg/dl; tTG 0.2 U/
mL), but an oral glucose tolerance test indicated hyperinsu-
linism (peak insulin level was 297 μU/mL), impaired glu-
cose tolerance (120’ glycaemia 179 mg/dl), and marked
insulin resistance (120’ insulin level 193 μU/mL).
Routine cytogenetic investigations revealed an apparently
normal female karyotype (46, XX). Chromosomal studies,
also using FISH, ruled out a 15q11.2-q13 deletion. Tests for
methylation and the presence of maternal uniparental di-
somy were both negative.
Given the numerous clinical features observed in this
subject, a FISH analysis utilising 41 subtelomere probes
was performed (Genzyme laboratories (Hawthorne, NY))
using Vysis probes (Downers Grove, IL). The results
were confirmed with a chromosome 1p subtelomere
probe (1pSUBTEL; Vysis) and the D1Z2 midi-satellite
probe with repeats in band 1p36 (Oncor), which is used
to confirm a common deletion interval (1p36.3).
Molecular karyotyping was performed by an array-CGH
analysis using the proband's DNA and an Agilent 44 K
array platform with a resolution of approximately 100 kb.
Based on the physical mapping positions designated in the
March 2006 assembly (NCBI36/hg18) of the UCSC Gen-
ome Browser, this analysis showed a deletion of approxi-
mately 1.5 Mb that involved the 1p36.33 region, with the
breakpoint falling between 554,268 bp (first-deleted oligo-
mer) and 2,133,973 bp (last-deleted oligomer) (Figure 2a).
Clinical report 2
The female patient, 10 years 1 month of age, was referred
to the Genetics and Molecular Medicine Unit of Anna
Meyer Children’s University Hospital for severe obesity
and suspected Prader-Willi syndrome.
The proposita was the second-born child of a noncon-
sanguineous marriage who was delivered normally at 39
weeks after an uncomplicated pregnancy. The family his-
tory was unremarkable in terms of obesity. The patient
has a brother with normal staturo-ponderal growth who
was 6 yrs old at the time of this study.
The Apgar score was 6I-9V-9X; as an infant, she required
oral suctioning, oxygen and stimulation at delivery for
treatment of cyanosis. Her birth weight was 2.360 kg
(-1.92 SDS; <3rd centile), her length was 44.6 cm (-2.24
SDS; <3rd centile), and her head circumference was
32 cm (-1.90 SDS; <3rd centile). Central hypotonia
occurred soon after birth. The screening for neonatal
congenital hypothyroidism was negative, but she experi-
enced recurrent respiratory infections throughout the
first year of life.
At 6 months of age, persistence of patent ductus arter-
iosus (PDA), which lead to pulmonary hypertension, was
diagnosed; PDA was closed at 7 months. She presented
Table 1 Clinical findings in patients with 1p36 deletion syndrome and Prader-Willi-like phenotype
Clinical findings Case
1
Case
2
D’Angelo et al.,
2006 [11]
D’Angelo
et al., 2010 [23]
Eugster et al.,
1997 [21]
Tsuyusaki
et al., 2010 [24]
Tsuyusaki
et al., 2010 [24]
Microcephaly + + - - - - -
Brachycephaly + + - - + - -
Straight eyebrows + + + + + +
Deep-set eyes + + +/- +/- + + +
Epicanthal folds + + - - - - -
Broad nasal root/bridge + + - - + + -
Posteriorly rotated/low-set/abnormal ears + + - - - + -
Pointed chin + + - - + + -
Midface hypoplasia + + - - + + +
Short feet + + + + + + +
Developmental delay + + + + + + +
Mental retardation + + + + + + +
Hypotonia + + + + + + +
Seizures + + - - + + +
Brain abnormalities - - - + +
Sensorineural deafness +/- +/- - - + +/- -
Strabismus + + - - + - -
Expressive language (poor/absent) + + + + + + +
Behavioural disorders + + + + + + +
Heart abnormalities - - - - ND + -
Renal abnormalities - - - - ND - -
External genitalia abnormalities - - - - ND - -
Poor neonatal weight + + + + +/- + -
Poor neonatal length + + + + ND - +
Hyperphagia + + + + + + +
Obesity + + + + + + +
Hyperinsulinism + + ND ND ND ND ND
Thyroid disorders - - + (thyroid nodules) + ND ND ND
+ = present.
- = not present.
ND = not determined.
Figure 1 Case 1 at 4 years 2 months of age (1a), and case 2 at 6 years 8 months of age (1b). In these patients, there is evidence of some
of the typical facial dysmorphisms of 1p36 deletion syndrome with Prader-Willi-like phenotype.
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Figure 2 Array-CGH analysis showing a deletion of approximately 1.5 Mb that involved the 1p36.33 region, with the breakpoint falling
between 554,268 bp and 2,133,973 bp (2a), and a deletion of approximately 2.5 Mb that involved the 1p36.33 – 1p36.32 region, with
the breakpoint falling between 564,424 bp and 3,111,905 bp (2b).
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to sit upright at 9 months, walk independently at 17
months and demonstrated use of language at 19 months.
Bilateral neurosensory deafness was diagnosed at 1 year
of age. The child developed significant hyperphagia.
At 10 yrs 1 month of age, the proposita showed a pheno-
type consistent with Prader-Willi syndrome: the patient
weighed 52.600 kg (1.65 SDS; 90-97th centile), her length
was 131.8 cm (-1.18 SDS; 10th centile), and her BMI
was 27.7 (2.02 SDS; > > 97th centile). The pubertal sta-
ging was defined as B1-PH2-3-AH2. Blood pressure
evaluation showed systolic and diastolic hypertension
(124/85 mmHg).
At the evaluation, she was observed to have numerous
dysmorphic features, including substantial truncular obes-
ity, scoliosis, small hands and feet, a small mouth with
heaped-up palate, a small chin and a small folded ear,
straight eyebrows, fifth finger clinodactyly and short toes,
and a mild learning disability. Examination of the mother
revealed some mild dysmorphism, clinodactyly of the fifth
finger, and a mild learning disability (Figure 1b).
An analysis of basal hormone levels showed normal
free thyroxine (13.7 pmol/L; range 10.3-19.4 pmol/L),
TSH (2.6 mIU/L; range, 0.4-4.0), cortisol (14.1 ug/dL;
range 5.0-19.0) and ACTH 14.1 (range 9.0-52.0 ng/L)
values. The blood count was also normal, and her blood
chemistry was as follows: AST: 20 IU/L, ALT: 21 IU/L,
γ-GTP: 32 IU/L, HbA1c: 5.5%, TG: 146 mg/dL, total
cholesterol: 259 mg/dL, HDL: 45 mg/dL, prolactin: 271
mIU/L, HbA1c: 6.6%, insulin: 49.2 μU/ml, glycemia
122 mg/dl (HOMA-R 14.82). The screening for coeliac
disease was negative (IgA 165 mg/dl; tTG 0.4 U/mL),
and an oral glucose tolerance test indicated diabetesmellitus (120’ glycaemia 234 mg/dl), with marked hy-
perinsulinism and insulin resistance (peak insulin level
was 279 μU/mL, 120’ insulin level 167 μU/mL).
Routine cytogenetic investigations revealed an appar-
ently normal female karyotype (46, XX). Chromosomal
studies, which also used FISH, ruled out a 15q11.2-q13
deletion found in Prader-Willi syndrome. The hypophys-
eal RMN revealed an empty sella.
At 12 yrs, 8 months, her height was 141 cm (-2.10
SDS; < 3rd centile), BMI was 29.9 (2.18 SDS; > 97th cen-
tile), and pubertal staging was described as B2-3-PH4-
AH2. Menarche started at 13 years of age.
At 16 years of age, her height was 145 cm (-2.82 SDS; <
3rd centile), her weight was 56.000 kg (0.05 SDS; 50-75th
centile), and pubertal staging was found to be B5-PH5-
AH3.
Tests for methylation and the presence of maternal uni-
parental disomy were both negative. Therefore, given the
numerous clinical features observed in this subject, a FISH
analysis utilising 41 subtelomere probes was performed
(Genzyme laboratories (Hawthorne, NY), using Vysis
probes (Downers Grove, IL). The results were confirmed
with a chromosome 1p subtelomere probe (1pSUBTEL;
Vysis) and the D1Z2 midi-satellite probe with repeats in
band 1p36 (Oncor). The D1Z2 probe is used for the con-
firmation of a common deletion interval (1p36.3). Array-
CGH was performed using the Agilent Human Genome
CGH microarray kit 180 K, with a resolution of approxi-
mately 40 kb. Break point positions were reported accord-
ing to Hg19, with build 37 falling between 564,424 bp
(first-deleted oligomer) and 3,111,905 bp (last-deleted oligo-
mer), which showed a deletion of approximately 2.5 Mb
that involved the 1p36.33 – 1p36.32 region (Figure 2b).
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Monosomy 1p36 is a common deletion syndrome that
produces specific physical characteristics, such as dis-
tinctive facial anomalies (pointed chin, flat nose, low-set
ears), cardiovascular malformations (atrial septal defect,
patent ductus arteriosus, tetralogy of Fallot), central
nervous system defects (mental retardation, cranial
nerve abnormalities, sensorineural hearing loss), neo-
natal hypotonia, cortical dysplasia, and seizures [2,9,10].
Affected individuals can display outbursts, a tendency
towards violent and self-injurious behaviour, as well as
autistic-like behaviours [5].
In patients with monosomy 1p36, the presence of
obesity has been poorly defined, and glucose metabolism
disorders have been infrequently reported to date. For
example, D'Angelo et al. [11] identified 1 case of dia-
betes in a 13-year old patient, from within a group of 41
patients with a Prader-Willi-like phenotype, who had a
pure 1p36 deletion. However, a study that evaluated the
glucose metabolism in subjects with 1p36 deletion syn-
drome had not been performed until our current study.
Our case reports confirm this association and suggest
that this phenotype may be associated with obesity in
some 1p36 patients. We also present evidence that hy-
perinsulinism and impaired glucose tolerance or diabetes
mellitus may be present in these patients and that these
features can occur in younger patients.
In fact, genome-wide linkage studies suggest that the
1p36 region shows a strong correlation with several traits
normally associated with metabolic syndrome (MetS) [12],
such as hyperlipidaemia, diabetes, obesity, arterial hyper-
tension, and BMI cluster [13,14].
Prader-Willi-like phenotype has been described in pa-
tients with chromosomal duplications [15,16], Fragile X
syndrome [17], udp(14)mat [18,19], and 6q deletion syn-
drome [20].
Obesity and/or hyperphagia are features rarely described
in patients with 1p 36 deletion [1,11,21-24], but correla-
tions between the extents of the deleted chromosomal seg-
ments have not been comprehensively provided. A
hypothesis for the similarity between patients with a 1p36
deletion and those with Prader-Willi syndrome, as well as
for the existence of two different phenotypes for a 1p36
microdeletion, has been suggested [23]. Contrary to its
manifestation in 1p36 deletion syndrome, obesity is a com-
mon clinical sign associated with mental retardation, and is
clearly a public health problem. Thus, a suitable question
to ask is whether these patients, who were described as be-
ing obese, are really representative of this particular dele-
tion syndrome [25].
To help paediatric neurologists and other professionals
in the recognition of this emerging and common chromo-
somal syndrome and to identify the possible overlap of
clinical presentations between patients with 1p36 deletionsyndrome and patients with a Prader-Willi like phenotype,
we have reviewed published articles that describe patients
with these features.
D’angelo et al. [23] described samples from 26 patients
with Prader-Willi-like phenotype that were analysed with
a 1p-specific subtelomeric probe, where one terminal de-
letion was identified in one patient. This patient did not
have any of the obvious features that resembled this
monosomy, but her clinical and behavioural features
were quite similar to those observed in patients with
PWS, except for the presence of normal sucking at birth.
The extent of the deletion could be limited to the most-
terminal 2.5 Mb of 1p36, within the chromosomal re-
gion 1p36.33–1p36.32, that is smaller than that usually
observed in monosomy 1p36 patients. Slavotinek et al.
[5] reviewed 39 cases reported to have pure 1p36 dele-
tions and 2 cases (5.1%) that demonstrated the Prader-
Willi-like phenotype. Shapira et al. [1] described 13
cases of the pure 1p36 deletion and found 2 cases (15%)
of obesity. Therefore, chromosome 1p36.33 deletion
should be investigated in patients with hypotonia, devel-
opmental delay, obesity and/or hyperphagia and behav-
ioural problems who test negative for PWS, which might
suggest non-classical manifestations of this disorder in
these patients [23].
Thus far, no individual gene within this region has
been conclusively determined to be causative of any
component of the phenotype [23]. However, in patients
with 1p36 deletion syndrome and PWS-like phenotype,
the possible involvement of the terminal 4 Mb of
chromosome 1p36 may be postulated [24].
Interestingly, D’Angelo et al. [23] have found that
some genes located near 1p36 may be involved in carbo-
hydrate or lipid metabolism or insulin signalling. Some
of these genes may be implicated in the Prader-Willi-like
phenotype typical of some monosomy 1p36 patients
through a mechanism of either haploinsufficiency, pos-
ition effect or gene interactions (epistasis) [23]. This may
be important because the 1p34 –36 region has shown
significant genome-wide linkage to premature myocar-
dial infarction [26].
Approximately 90% of the 1p rearrangements are less
than 10 Mb in size [3], and it is assumed that quite a
number of subjects are misdiagnosed [3]. Moreover,
several subjects diagnosed with monosomy 1p36 have
been reported to have mild or atypical phenotypes or
presenting features that overlap with other genetic syn-
dromes [11,27-29].
In conclusion, our case reports confirm that some pa-
tients with 1p36 monosomy may show a Prader-Willi-like
physical phenotype and that this aspect may therefore be
overlooked, which may result in this condition being
underdiagnosed. These patients may show such character-
istics as obesity with hyperinsulinism and impaired glucose
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ate this aspect.
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